Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference

Dizal Showcases Lung Cancer Research at 2025 WCLC

At the recent 2025 World Conference on Lung Cancer (WCLC) held in Barcelona, Spain, Dizal Pharmaceutical (SSE:688192) made headlines with the presentation of its significant research findings related to lung cancer treatments. The company has a strong commitment to advancing biopharmaceutical solutions for cancer and immunological diseases.

ZEGFROVY: A Pioneering Therapy for NSCLC

Dizal's leading candidate, ZEGFROVY (sunvozertinib), has garnered attention for its therapeutic efficacy in treating non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Recent findings from the pivotal WU-KONG1 Part B (WU-KONG1B) study were disclosed during an oral session at the conference and concurrently published in the Journal of Clinical Oncology.

ZEGFROVY received accelerated approval from the U.S. FDA in July 2025, marking its position as the sole targeted oral therapy available for patients with NSCLC who have EGFR exon20ins. The treatment demonstrated a favorable benefit/risk profile, showcasing robust and durable antitumor activity among patients previously treated with platinum-based chemotherapy.

Study Findings: Key Highlights

Among the notable presentations was ZEGFROVY's impressive outcomes across various NSCLC patient groups, including those with uncommon EGFR mutations, HER2 mutations, and patients who were resistant to EGFR TKIs. Data revealed high objective response rates (ORR) and disease control rates (DCR). In particular, ZEGFROVY combined with anlotinib achieved an ORR of over 80% and a DCR of 100% in treatment-naïve patients with EGFR exon20ins NSCLC.

Moreover, the combination of ZEGFROVY with bevacizumab yielded a DCR of 100% in patients previously treated, with 85.7% observing shrinkage in their target lesions. Neoadjuvant therapy results were also promising, with patients showing significant responses prior to surgery.

ZEGFROVY not only demonstrated efficacy but also maintained a manageable safety profile throughout the trials, with the most common adverse events being mild and easily addressed.

Golidocitinib: A New Hope for Resistant NSCLC

In addition to ZEGFROVY, Dizal highlighted its ongoing studies involving golidocitinib, a selective Janus kinase 1 (JAK1) inhibitor being assessed in combination with anti-PD-1 therapies for treatment-resistant NSCLC. Early results have shown that this combination is well-tolerated and may provide a new therapeutic pathway for patients who have limited options following immune checkpoint inhibitor therapy.

Dr. Xiaolin Zhang, CEO of Dizal, expressed commitment to addressing the unmet medical needs in NSCLC by focusing on innovative therapies for EGFR mutations. He anticipates that through scientific innovation, Dizal aims to deliver transformative treatments to patients globally.

Overview of Dizal's Commitment

Dizal is dedicated to creating groundbreaking treatments, prioritizing first-in-class medicines for cancer and immunological conditions. Their research is underscored by a solid foundation in translational science, resulting in an internationally competitive portfolio. Key assets include ZEGFROVY, which has been approved in both the U.S. and China, and golidocitinib, which has also secured approval in China.

To learn more about their research and continued advancements in cancer treatment, visit Dizal's website or follow them on social media platforms.

Conclusion

The advancements showcased by Dizal at the WCLC reflect a significant step forward in lung cancer therapies, providing hope for patients and the medical community alike as they rigorously address critical treatment gaps within the field of oncology.